Associations Between Short‐Term Changes in Disease Activity and Long‐Term Clinical Outcomes in Activated Phosphoinositide 3‐Kinase Delta Syndrome
Journal of Immunology Research · 2026
DOI: 10.1155/jimr/1486611 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Immunology Research, 2026. Verfasst von Joanne Tutein Nolthenius und 6 weiteren Autor:innen. Beteiligte Einrichtung: Pharming Group N.V., Leiden, Netherlands. Hauptthemen laut MEDLINE: Class I Phosphatidylinositol 3-Kinases, Primary Immunodeficiency Diseases, Genetic Diseases, X-Linked. Die Arbeit nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Pharming Group N.V..
Abstract (Originalsprache)
Background
Clinical trials in activated phosphoinositide 3‐kinase delta (PI3Kδ) syndrome (APDS), an ultra‐rare disease, have evaluated treatment response to the PI3Kδ inhibitor leniolisib using disease activity endpoints, including those measuring immunodeficiency and immune dysregulation. However, the relationship between disease activity endpoints and long‐term clinical outcomes has not been quantified.
Methods
Data from a randomised controlled trial and its open‐label extension (OLE) investigating leniolisib were used to evaluate associations between short‐term disease activity endpoints and longer‐term clinical outcomes. Both single time point and repeated measures analyses were conducted using linear regression modelling and random effects multilevel regression modelling, respectively.
Results
In total, 39 patients were included (≤6 years of follow‐up). Improvements in multiple immunodeficiency and dysregulation disease activity endpoints were significantly associated with increases in the patient global assessment (PtGA) and the 36‐item short form survey (SF‐36) physical component score and mental component score (PCS/MCS). Increasing proportion of naïve B cells was associated with reduction in infection rates (2.3% fewer infections per 1% increase in naïve B cells).
Conclusions
In this clinical trial setting, short‐term improvements in immunodeficiency and dysregulation following treatment with leniolisib were associated with longer‐term improvements in clinical outcomes, including infection rates and quality of life, for patients with APDS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pharming Group N.V., Leiden, Netherlands.
- Visible Analytics, Oxford, UK.
- Department of Immunology, University Hospital Motol and Homolka, 2nd Faculty of Medicine, Charles University, Prague, Czech Republic, cuni.cz.
ORCID-Profile: Joanne Tutein Nolthenius, Anna Šedivá
Förderung
- Pharming Group N.V.
Zitieren
APA
Nolthenius, J. T., Torlinska, B., Linsell, L., Hawkins, N., Chen, Y., Whalen, J., & Šedivá, A. (2026). Associations Between Short‐Term Changes in Disease Activity and Long‐Term Clinical Outcomes in Activated Phosphoinositide 3‐Kinase Delta Syndrome. Journal of Immunology Research. https://doi.org/10.1155/jimr/1486611
Vancouver
Nolthenius JT, Torlinska B, Linsell L, Hawkins N, Chen Y, Whalen J, et al. Associations Between Short‐Term Changes in Disease Activity and Long‐Term Clinical Outcomes in Activated Phosphoinositide 3‐Kinase Delta Syndrome. Journal of Immunology Research. 2026. doi:10.1155/jimr/1486611
BibTeX
@article{Nolthenius2026,
author = {Nolthenius, Joanne Tutein and Torlinska, Barbara and Linsell, Louise and Hawkins, Neil and Chen, Yuxian and Whalen, John and Šedivá, Anna},
title = {Associations Between Short‐Term Changes in Disease Activity and Long‐Term Clinical Outcomes in Activated Phosphoinositide 3‐Kinase Delta Syndrome},
journal = {Journal of Immunology Research},
year = {2026},
doi = {10.1155/jimr/1486611}
}
EUVIMED